Advanced search
Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 10, 2003 - Issue 4
Submit an article Journal homepage
76
Views
104
CrossRef citations to date
0
Altmetric
Original Article

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

Angela Dispenzieri Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
Martha Q. Lacy Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
S. Vincent Rajkumar Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
Susan M. Geyer Department of Biostatistics, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
Thomas E. Witzig Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
Rafael Fonseca Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
John A. Lust Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
Philip R. Greipp Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
,
Robert A. Kyle Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
&
Morie A. Gertz Division of Hematology and the Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA
 show all
Pages 257-261 | Received 19 Mar 2003, Accepted 27 Jun 2003, Published online: 06 Jul 2009

Citations (104)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (12)

Ashutosh D. Wechalekar, M. Teresa Cibeira, Simon D. Gibbs, Arnaud Jaccard, Shaji Kumar, Giampaolo Merlini, Giovanni Palladini, Vaishali Sanchorawala, Stefan Schönland, Christopher Venner, Mario Boccadoro & Efstathios Kastritis. (2023) Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid 30:1, pages 3-17.
Read now
Mario Nuvolone, Marco Basset & Giovanni Palladini. (2021) A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis. Expert Opinion on Drug Safety 20:4, pages 411-426.
Read now
Shayna Sarosiek & Vaishali Sanchorawala. (2019) Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives. Journal of Blood Medicine 10, pages 373-380.
Read now
Piotr Kozlowski, Scott Montgomery, Rahel Befekadu & Victoria Hahn-Strömberg. (2017) The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits. Journal of Blood Medicine 8, pages 29-34.
Read now
Ji Yun Lee, Sung Hee Lim, Seok Jin Kim, Ga Yeon Lee, Jung Eun Lee, Jin-Oh Choi, Jung-Sun Kim, Hee-Jin Kim, Soo-Youn Lee, Ju-Hong Min, Eun-Seok Jeon & Kihyun Kim. (2014) Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid 21:4, pages 261-266.
Read now
Giampaolo Merlini, Raymond L Comenzo, David C Seldin, Ashutosh Wechalekar & Morie A Gertz. (2014) Immunoglobulin light chain amyloidosis. Expert Review of Hematology 7:1, pages 143-156.
Read now
Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger & Klaus Podar. (2012) Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opinion on Pharmacotherapy 13:4, pages 473-494.
Read now
Cheng E Chee, Angela Dispenzieri & Morie A Gertz. (2010) Amyloidosis and POEMS syndrome. Expert Opinion on Pharmacotherapy 11:9, pages 1501-1514.
Read now
Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, Nelson Leung & Mark Litzow. (2008) Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leukemia & Lymphoma 49:1, pages 36-41.
Read now
Efstathios Kastritis & Meletios A Dimopoulos. (2007) The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy 8:4, pages 497-509.
Read now
Archana Roy & Vivek Roy. (2006) Primary systemic amyloidosis. Postgraduate Medicine 119:1, pages 93-99.
Read now
Angela Dispenzieri & Morie A Gertz. (2005) Treatment options for POEMS syndrome. Expert Opinion on Pharmacotherapy 6:6, pages 945-953.
Read now

Articles from other publishers (92)

Angela Dispenzieri. 2023. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 423 432 .
Man (Melody) Luo, Peijuan (Penny) Zhu, Ivo Nnane, Yuan Xiong, Giampaolo Merlini, Raymond L Comenzo, Efstathios Kastritis, Ashutosh D. Wechalekar, Brendan M. Weiss, NamPhuong Tran, Xiang Qin, Jessica Vermeulen, Amarnath Sharma, Yu‐Nien Sun & Honghui Zhou. (2021) Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis. The Journal of Clinical Pharmacology 62:5, pages 656-669.
Crossref
Angela Dispenzieri, Efstathios Kastritis, Ashutosh D. Wechalekar, Stefan O. Schönland, Kihyun Kim, Vaishali Sanchorawala, Heather J. Landau, Fiona Kwok, Kenshi Suzuki, Raymond L. Comenzo, Deborah Berg, Guohui Liu, Arun Kumar, Douglas V. Faller & Giampaolo Merlini. (2021) A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis. Leukemia 36:1, pages 225-235.
Crossref
M. Hasib Sidiqi & Morie A. Gertz. (2021) Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer Journal 11:5.
Crossref
Cindy Varga & Chakra Chaulagain. (2020) Options for Chemotherapy and Scoring Response and Relapse. Hematology/Oncology Clinics of North America 34:6, pages 1115-1131.
Crossref
Despina Fotiou, Meletios Athanasios Dimopoulos & Efstathios Kastritis. (2020) Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. HemaSphere 4:4, pages e454.
Crossref
Morie A. Gertz. (2020) Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. American Journal of Hematology 95:7, pages 848-860.
Crossref
Joselle Cook, Eli Muchtar & Rahma Warsame. (2020) Updates in the Diagnosis and Management of AL Amyloidosis. Current Hematologic Malignancy Reports 15:3, pages 155-167.
Crossref
Iuliana Vaxman, Angela Dispenzieri, Eli Muchtar & Morie Gertz. (2020) New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Reviews 40, pages 100636.
Crossref
Layla Van Doren & Suzanne Lentzsch. (2020) Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis. Acta Haematologica 143:4, pages 373-380.
Crossref
S. Vincent Rajkumar & Angela Dispenzieri. 2020. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1884 1910.e7 .
Efstathios Kastritis, Ioanna DialoupiMaria GavriatopoulouMaria RoussouNikolaos KanelliasDespina FotiouIoannis Ntanasis-Stathopoulos, Elektra PapadopoulouDimitrios C. Ziogas, Kimon Stamatelopoulos, Efstathios ManiosArgyrios NtalianisEvangelos Eleutherakis-Papaiakovou, Asimina Papanikolaou, Magdalini MigkouAristea-Maria PapanotaHarikleia Gakiopoulou, Erasmia PsimenouMaria Irini TselegkidiOurania Tsitsilonis, Ioannis Kostopoulos, Evangelos Terpos & Meletios A. Dimopoulos. (2019) Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood Advances 3:20, pages 3002-3009.
Crossref
Romana Ryšavá. (2019) AL amyloidosis: advances in diagnostics and treatment. Nephrology Dialysis Transplantation 34:9, pages 1460-1466.
Crossref
Cindy Varga, Stephanie E. Titus, Denis Toskic & Raymond L. Comenzo. (2019) Use of novel therapies in the treatment of light chain amyloidosis. Blood Reviews 37, pages 100581.
Crossref
Iuliana Vaxman & Morie Gertz. (2019) Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. Acta Haematologica 141:2, pages 93-106.
Crossref
Giampaolo Merlini, Angela Dispenzieri, Vaishali Sanchorawala, Stefan O. Schönland, Giovanni Palladini, Philip N. Hawkins & Morie A. Gertz. (2018) Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers 4:1.
Crossref
Morie A. Gertz. (2018) Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. American Journal of Hematology 93:9, pages 1169-1180.
Crossref
Morie A. Gertz. (2018) Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer Journal 8:5.
Crossref
Chihiro Shimazaki, Hiroyuki Hata, Sinsuke Iida, Mitsuharu Ueda, Nagaaki Katoh, Yoshiki Sekijima, Shuichi Ikeda, Masahide Yazaki, Wakaba Fukushima & Yukio Ando. (2018) Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan. Internal Medicine 57:2, pages 181-187.
Crossref
Morie A. Gertz, Francis K. Buadi, Taimur Sher & Angela Dispenzieri. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 651 672 .
Anita D'Souza, Kathryn Flynn, Saurabh Chhabra, Binod Dhakal, Mehdi Hamadani, Kirsten Jacobsen, Marcelo Pasquini, Dorothee Weihrauch & Parameswaran Hari. (2017) Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemporary Clinical Trials Communications 8, pages 33-38.
Crossref
Eli Muchtar, Morie A. Gertz, Shaji K. KumarMartha Q. LacyDavid DingliFrancis K. BuadiMartha Grogan, Suzanne R. HaymanPrashant KapoorNelson Leung, Amie FonderMiriam HobbsYi Lisa HwaWilson GonsalvesRahma WarsameTaxiarchis V. KourelisStephen RussellJohn A. LustYi LinRonald S. GoSteven ZeldenrustRobert A. KyleS. Vincent RajkumarAngela Dispenzieri. (2017) Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129:15, pages 2111-2119.
Crossref
Morie A. Gertz. (2016) Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. American Journal of Hematology 91:9, pages 947-956.
Crossref
Vaishali Sanchorawala, Anthony C. Shelton, Stephen Lo, Cindy Varga, J. Mark Sloan & David C. Seldin. (2016) Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood 128:8, pages 1059-1062.
Crossref
Xiang-Hua Huang & Zhi-Hong Liu. (2016) The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China. Kidney Diseases 2:1, pages 1-9.
Crossref
Eli Muchtar, Francis K. Buadi, Angela Dispenzieri & Morie A. Gertz. (2016) Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. Acta Haematologica 135:3, pages 172-190.
Crossref
Angela Dispenzieri & Giampaolo Merlini. 2016. Plasma Cell Dyscrasias. Plasma Cell Dyscrasias 273 318 .
Angela Dispenzieri, Francis Buadi, Shaji K. Kumar, Craig B. Reeder, Tamur Sher, Martha Q. Lacy, Robert A. Kyle, Joseph R. Mikhael, Vivek Roy, Nelson Leung, Martha Grogan, Prashant Kapoor, John A. Lust, David Dingli, Ronald S. Go, Yi Lisa Hwa, Suzanne R. Hayman, Rafael Fonseca, Sikander Ailawadhi, P. Leif Bergsagel, Ascher Chanan-Khan, S. Vincent Rajkumar, Stephen J. Russell, Keith Stewart, Steven R. Zeldenrust & Morie A. Gertz. (2015) Treatment of Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings 90:8, pages 1054-1081.
Crossref
Rabya H. Sayed, Philip N. Hawkins & Helen J. Lachmann. (2015) Emerging treatments for amyloidosis. Kidney International 87:3, pages 516-526.
Crossref
Ashutosh D. Wechalekar, Julian D. Gillmore, Jenny Bird, Jamie Cavenagh, Stephen Hawkins, Majid Kazmi, Helen J. Lachmann, Philip N. Hawkins & Guy Pratt. (2015) Guidelines on the management of AL amyloidosis. British Journal of Haematology 168:2, pages 186-206.
Crossref
Christi A. Hayes, Alla Keyzner, Michael Esposito & Craig E. Devoe. 2015. Onconephrology. Onconephrology 279 307 .
Morie A. Gertz. (2014) Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. American Journal of Hematology 89:12, pages 1132-1140.
Crossref
S. Vincent Rajkumar & Angela Dispenzieri. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1991 2017.e7 .
Ashutosh D. Wechalekar, Simon W. Dubrey & Raymond L. Comenzo. 2013. Myeloma. Myeloma 174 189 .
A Dispenzieri, K Seenithamby, M Q Lacy, S K Kumar, F K Buadi, S R Hayman, D Dingli, M R Litzow, D A Gastineau, D J Inwards, I N Micallef, S M Ansell, P B Johnston, L F Porrata, M M Patnaik, W J Hogan & M A A Gertz. (2013) Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.. Bone Marrow Transplantation 48:10, pages 1302-1307.
Crossref
M Rosenzweig, S Giralt & H Landau. (2012) Light-chain amyloidosis: SCT, novel agents and beyond. Bone Marrow Transplantation 48:8, pages 1022-1027.
Crossref
Morie A. Gertz. (2013) Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. American Journal of Hematology 88:5, pages 416-425.
Crossref
Moshe E. Gatt & Giovanni Palladini. (2013) Light chain amyloidosis 2012: a new era. British Journal of Haematology 160:5, pages 582-598.
Crossref
Morie A. Gertz & Robert A. Kyle. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 729 750 .
M A Rosenzweig, H Landau, D Seldin, C O'Hara, S Girnius, N Hanson, D Frosina, C Sedrak, M Arcila, R L Comenzo, S Giralt, S Gnjatic, A A Jungbluth & G Koehne. (2012) Cancer-testis antigen expression and immunogenicity in AL amyloidosis. Blood Cancer Journal 2:9, pages e90-e90.
Crossref
S. W. Dubrey & R. L. Comenzo. (2012) Amyloid diseases of the heart: current and future therapies. QJM 105:7, pages 617-631.
Crossref
Angela Dispenzieri, Morie A. Gertz & Francis Buadi. (2012) What do I need to know about immunoglobulin light chain (AL) amyloidosis?. Blood Reviews 26:4, pages 137-154.
Crossref
Angela DispenzieriFrancis Buadi, Kristina Laumann, Betsy LaPlant, Suzanne R. Hayman, Shaji K. Kumar, David DingliSteven R. Zeldenrust, Joseph R. Mikhael, Robert Hall, S. Vincent Rajkumar, Craig Reeder, Rafael Fonseca, P. Lief Bergsagel, A. Keith Stewart, Vivek Roy, Thomas E. WitzigJohn A. LustStephen J. RussellMorie A. Gertz & Martha Q. Lacy. (2012) Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 119:23, pages 5397-5404.
Crossref
Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Maria Gavriatopoulou, Constantinos Pamboukas, Ioannis Boletis, Smaragda Marinaki, Theofanis Apostolou, Nikitas Nikitas, Georgios Gkortzolidis, Eurydiki Michalis, Sossana Delimpasi & Meletios A. Dimopoulos. (2012) A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 119:23, pages 5384-5390.
Crossref
Shaji K. Kumar, Suzanne R. Hayman, Francis K. Buadi, Vivek Roy, Martha Q. Lacy, Morie A. Gertz, Jacob Allred, Kristina M. Laumann, Leif P. Bergsagel, David Dingli, Joseph R. Mikhael, Craig B. Reeder, A. Keith Stewart, Steven R. Zeldenrust, Philip R. Greipp, John A. Lust, Rafael Fonseca, Stephen J. Russell, S. Vincent Rajkumar & Angela Dispenzieri. (2012) Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 119:21, pages 4860-4867.
Crossref
Joseph R. Mikhael, Steven R. Schuster, Victor H. Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B. Reeder, A. Keith Stewart, P. Leif Bergsagel & Rafael Fonseca. (2012) Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119:19, pages 4391-4394.
Crossref
Shaji KumarAngela DispenzieriMartha Q. LacySuzanne R. HaymanFrancis K. BuadiColin ColbyKristina LaumannSteve R. ZeldenrustNelson LeungDavid DingliPhilip R. GreippJohn A. LustStephen J. RussellRobert A. KyleS. Vincent RajkumarMorie A. Gertz. (2012) Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements. Journal of Clinical Oncology 30:9, pages 989-995.
Crossref
M A Gertz. (2011) How to manage primary amyloidosis. Leukemia 26:2, pages 191-198.
Crossref
Morie A. Gertz. (2012) Immunoglobulin light chain amyloidosis: 2012 update on diagnosis, prognosis, and treatment. American Journal of Hematology 87:2, pages 183-189.
Crossref
Michael Rosenzweig & Heather Landau. (2011) Light chain (AL) amyloidosis: update on diagnosis and management. Journal of Hematology & Oncology 4:1.
Crossref
B M Hovey, J E Ward, P Soo Hoo, C J O'Hara, L H Connors & D C Seldin. (2011) Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Therapy 18:12, pages 1150-1156.
Crossref
Giovanni Palladini & Giampaolo Merlini. (2011) Transplantation vs. conventional-dose therapy for amyloidosis. Current Opinion in Oncology 23:2, pages 214-220.
Crossref
Morie A. Gertz. (2011) Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk‐stratification, and management. American Journal of Hematology 86:2, pages 180-186.
Crossref
Shaji K. Kumar, Morie A. Gertz, Martha Q. Lacy, David Dingli, Suzanne R. Hayman, Francis K. Buadi, Kristen Short-Detweiler, Steven R. Zeldenrust, Nelson Leung, Philip R. Greipp, John A. Lust, Stephen J. Russell, Robert A. Kyle, S. Vincent Rajkumar & Angela Dispenzieri. (2011) Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. Mayo Clinic Proceedings 86:1, pages 12-18.
Crossref
Angela Dispenzieri & Suzanne R. Hayman. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies 184 206 .
Angela Dispenzieri, David Dingli, Shaji K. Kumar, S. Vincent Rajkumar, Martha Q. Lacy, Suzanne Hayman, Frances Buadi, Stephen Zeldenrust, Nelson Leung, Kristen Detweiler‐Short, John A. Lust, Stephen J. Russell, Robert A. Kyle & Morie A. Gertz. (2010) Discordance between serum cardiac biomarker and immunoglobulin‐free light‐chain response in patients with immunoglobulin light‐chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology 85:10, pages 757-759.
Crossref
Angela Dispenzieri & Shaji Kumar. 2010. Protein Misfolding Diseases. Protein Misfolding Diseases 775 793 .
Efstathios KastritisAshutosh D. WechalekarMeletios A. DimopoulosGiampaolo MerliniPhilip N. HawkinsVittorio PerfettiJulian D. GillmoreGiovanni Palladini. (2010) Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. Journal of Clinical Oncology 28:6, pages 1031-1037.
Crossref
Simon W Dubrey & Rodney H Falk. (2010) Amyloid heart disease. British Journal of Hospital Medicine 71:2, pages 76-82.
Crossref
Adam D. Cohen & Raymond L. Comenzo. 2010. Amyloidosis. Amyloidosis 165 177 .
Morie A. Gertz & Francis Buadi. 2010. Amyloidosis. Amyloidosis 155 164 .
Ingrid I van Gameren, Edo Vellenga & Bouke PC Hazenberg. (2009) Novel treatments for systemic amyloidosis. International Journal of Clinical Rheumatology 4:2, pages 171-188.
Crossref
Morie A. Gertz & Steven R. Zeldenrust. (2009) Treatment of immunoglobulin light chain amyloidosis. Current Hematologic Malignancy Reports 4:2, pages 91-98.
Crossref
Kostandinos Sideras & Morie A. Gertz. 2009. Advances in Clinical Chemistry Volume 47. Advances in Clinical Chemistry Volume 47 1 44 .
Morie A. Gertz & Suzanne R. Hayman. 2009. Treatment of Multiple Myeloma and Related Disorders. Treatment of Multiple Myeloma and Related Disorders 112 128 .
M A Dimopoulos, E Kastritis & S V Rajkumar. (2008) Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 22:7, pages 1343-1353.
Crossref
Ashutosh D. Wechalekar, Philip N. Hawkins & Julian D. Gillmore. (2008) Perspectives in treatment of AL amyloidosis. British Journal of Haematology 140:4, pages 365-377.
Crossref
Angela Dispenzieri, Giampaolo Merlini & Raymond L. Comenzo. (2008) Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biology of Blood and Marrow Transplantation 14:1, pages 6-11.
Crossref
Joline L.T. Chen & Laura M. Dember. 2008. Therapy in Nephrology & Hypertension. Therapy in Nephrology & Hypertension 257 271 .
Vaishali Sanchorawala. 2009. Myeloma Therapy. Myeloma Therapy 551 569 .
Ashraf Badros. 2009. Myeloma Therapy. Myeloma Therapy 205 227 .
Vaishali SanchorawalaMartha SkinnerKaren Quillen, Kathleen T. FinnGheorghe Doros & David C. Seldin. (2007) Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 110:10, pages 3561-3563.
Crossref
Tatiana Prokaeva, Brian Spencer, Maurya Kaut, Al Ozonoff, Gheorghe Doros, Lawreen H. Connors, Martha Skinner & David C. Seldin. (2007) Soft tissue, joint, and bone manifestations of AL amyloidosis: Clinical presentation, molecular features, and survival. Arthritis & Rheumatism 56:11, pages 3858-3868.
Crossref
Morie A. Gertz. 2007. Multiple Myeloma: Translational and Emerging Therapies. Multiple Myeloma: Translational and Emerging Therapies 261 276 .
Adam D. Cohen, Ping Zhou, Joanne Chou, Julie Teruya-Feldstein, Lilian Reich, Hani Hassoun, Beth Levine, Daniel A. Filippa, Elyn Riedel, Tarun Kewalramani, Michael D. Stubblefield, Martin Fleisher, Stephen Nimer & Raymond L. Comenzo. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal of Haematology 139:2, pages 224-233.
Crossref
V Sanchorawala, D G Wright, K Quillen, K T Finn, L M Dember, J L Berk, G Doros, C Fisher, M Skinner & D C Seldin. (2007) Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplantation 40:6, pages 557-562.
Crossref
Ashutosh D. Wechalekar, Hugh J. B. Goodman, Helen J. Lachmann, Mark Offer, Philip N. Hawkins & Julian D. Gillmore. (2006) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:2, pages 457-464.
Crossref
Angela Dispenzieri, Martha Q. LacySteven R. ZeldenrustSuzanne R. HaymanShaji K. KumarSusan M. GeyerJohn A. Lust, Jacob B. AllredThomas E. Witzig, S. Vincent RajkumarPhilip R. Greipp, Stephen J. Russell, Brian KabatMorie A. Gertz. (2006) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:2, pages 465-470.
Crossref
Vaishali SanchorawalaDaniel G. WrightMichael RosenzweigKathleen T. FinnSalli FennesseyJerome B. Zeldis, Martha SkinnerDavid C. Seldin. (2006) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109:2, pages 492-496.
Crossref
Laura M. Dember. (2006) Amyloidosis-Associated Kidney Disease. Journal of the American Society of Nephrology 17:12, pages 3458-3471.
Crossref
Vaishali Sanchorawala. (2006) Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology 1:6, pages 1331-1341.
Crossref
Bhawna Sirohi & Ray Powles. (2006) Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. European Journal of Cancer 42:11, pages 1671-1683.
Crossref
S. Vincent Rajkumar, Angela Dispenzieri & Robert A. Kyle. (2006) Monoclonal Gammopathy of Undetermined Significance, Waldenström Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment. Mayo Clinic Proceedings 81:5, pages 693-703.
Crossref
Raymond L. Comenzo. (2006) Amyloidosis. Current Treatment Options in Oncology 7:3, pages 225-236.
Crossref
P. Campbell & C. Murdock. (2006) Cardiac amyloidosis-sustained clinical and free light chain response to low dose thalidomide and corticosteroids. Internal Medicine Journal 36:2, pages 137-139.
Crossref
Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri & Suzanne R. Hayman. (2005) Amyloidosis. Best Practice & Research Clinical Haematology 18:4, pages 709-727.
Crossref
Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri & Suzanne R. Hayman. (2005) Amyloidosis: Diagnosis and Management. Clinical Lymphoma and Myeloma 6:3, pages 208-219.
Crossref
D Ribatti & A Vacca. (2005) Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 19:9, pages 1525-1531.
Crossref
Giovanni PalladiniVittorio PerfettiStefano PerliniLaura ObiciFrancesca LavatelliRiccardo CaccialanzaRosangela InvernizziBenedetto ComottiGiampaolo Merlini. (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:7, pages 2949-2951.
Crossref
David C. Seldin. (2004) Interfering with amyloidosis. Blood 104:12, pages 3419-3420.
Crossref
Morie Gertz. 2004. Amyloid and Amyloidosis. Amyloid and Amyloidosis 148 150 .
Morie A. Gertz, Giampaolo Merlini & Steven P. Treon. (2004) Amyloidosis and Waldenström’s Macroglobulinemia. Hematology 2004:1, pages 257-282.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.